Q3 2015 13F Holders as of 30 Sep 2015
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
1,918,254
-
Share change
-
+124,024
-
Total reported value
-
$4,394,000
-
Put/Call ratio
-
70%
-
Price per share
-
$2.29
-
Number of holders
-
19
-
Value change
-
+$244,904
-
Number of buys
-
7
-
Number of sells
-
3
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q3 2015
As of 30 Sep 2015,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,918,254 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., NORTHERN TRUST CORP, Bank of New York Mellon Corp, M&T Bank Corp, and Psagot Investment House Ltd..
This page lists
19
institutional shareholders reporting positions in this security
for the Q3 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.